Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7092270 | 0.80 | DAO (0.44) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL151278 | 0.78 | PIK3CA (0.44) | HTTALDH1A1DAO | |
| SCHEMBL3764973 | 0.78 | SLC6A2 (0.44) | DAO | |
| SCHEMBL3751790 | 0.78 | KDM4E (0.47) | ALDH1A1MAOAMAOBRAB9A | |
| SCHEMBL4429458 | 0.78 | DAO (0.44) | ALDH1A1DAORAB9A | |
| SCHEMBL3746892 | 0.78 | MAPT (0.45) | — | |
| SCHEMBL8079708 | 0.78 | KDM1A (0.37) | ALDH1A1KDM1A | |
| SCHEMBL27855836 | 0.78 | ALDH1A1 (0.50) | ALDH1A1RAB9A | |
| SCHEMBL16105820 | 0.78 | DAO (0.55) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3299911 | 0.78 | CYP17A1 (0.52) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | claimed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | claimed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | claimed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | claimed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2021224865-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | claimed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | MERCK SHARP & DOHME CORP. | 2006-04-06 | — | — | US | claimed |
| US-6677452-B1 | PREPARED BY REACTING AMINE WITH PYRIDINE SUBSTITUTED WITH HALOGEN AT POSITION 6 AND WITH CARBOXY OR SULFONYL GROUP AT ANOTHER POSITION TO FORM AMIDE OR SULFONAMIDE, DISPLACING HALOGEN WITH DESIRED DIAMINE | LION BIOSCIENCE AG (DE) | 2004-01-13 | — | — | US | claimed |
| EP-1218343-A4 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2003-06-18 | — | — | EP | claimed |
| EP-1218343-A1 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001025203-A1 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-12 | — | — | WO | claimed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | claimed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | HTT 1072/4885ALDH1A1 3200/4885CYP17A1 4010/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | HTT 1072/4885ALDH1A1 3200/4885CYP17A1 4010/4885 |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | HTT 1072/4885ALDH1A1 3200/4885CYP17A1 4010/4885 |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | HTT 1911/4885ALDH1A1 1756/4885CYP17A1 3845/4885 |
| US-20060074120-A1 | cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism | NR3C1, NR3C2, NR5A1 | HTT 4641/4885ALDH1A1 1631/4885CYP17A1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.